Viridian Therapeutics gains long-term potential from extended-acting FcRn drug, Jefferies says
Jefferies highlights Viridian Therapeutics' (VRDN) VRDN-008 as a potential best-in-class FcRn inhibitor, with an extended half-life supporting eight-week dosing. Phase I results showed a 74% peak IgG reduction sustained for eight weeks. The company plans to start a registrational study in gMG in mid-2027, with potential approval by 2031. Jefferies maintains a $35 price target, excluding contributions from VRDN's broader pipeline.
How this was made

The 30-second read
Why it matters
The Phase I results provide a tangible efficacy signal and a differentiated dosing regimen, supporting a higher valuation outlook.
Market read
Positive early data may trigger buying interest in VRDN and influence peer valuations in the FcRn inhibitor niche.
What to watch
Potential competition from argenx's ARGX‑213 and uncertainty around regulatory timelines.
Background
Jefferies highlights VRDN-008 as a best‑in‑class FcRn inhibitor with an eight‑week dosing schedule, targeting generalized myasthenia gravis first.
Ticker impact
Jefferies reports positive Phase I data for VRDN-008, showing a 15‑18 day half‑life and ~74% IgG reduction, marking the first public disclosure of these results.
likely upward pressure as the market prices in the extended half‑life advantage.
Phase I results are material for a biotech and the broker assigns a $35 price target, indicating belief in significant upside.
Market effects
The data may boost the broader FcRn inhibitor space, prompting re‑valuation of peers such as argenx.
US biotech sector could see modest gains as investors reassess pipeline timelines.
Limited to biotech investors; no broad market impact.
Counterpoint
The on‑body injector delivery could limit adoption, tempering upside.
Key entities
- companyViridian Therapeutics
NASDAQ‑listed biotech developing VRDN‑008.
- analystJefferies
Equity research firm issuing the upgrade and price target.

